Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 12/20 | 0.83 |
| ▸ | DRD1 | P21728 | 12/20 | 0.83 |
| ▸ | DRD5 | P21918 | 2/20 | 0.78 |
| ▸ | DRD3 | P35462 | 2/20 | 0.78 |
| ▸ | DRD4 | P21917 | 1/20 | 0.67 |
| ▸ | RAD52 | P43351 | 1/20 | 0.63 |
| ▸ | HTR1A | P08908 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16627009 | 1.00 | DRD2 (0.83) | DRD2DRD1DRD5DRD3DRD4 | |
| SCHEMBL16627062 | 1.00 | DRD2 (0.83) | DRD2DRD1DRD5DRD3DRD4 | |
| SCHEMBL14234709 | 0.92 | RAD52 (0.75) | DRD2DRD1DRD5DRD3DRD4 | |
| SCHEMBL14235263 | 0.92 | RAD52 (0.75) | DRD2DRD1DRD5DRD3DRD4 | |
| SCHEMBL18626358 | 0.91 | DRD2 (0.69) | DRD2DRD1DRD5DRD3DRD4 | |
| SCHEMBL14235140 | 0.91 | DRD1 (1.00) | DRD2DRD1DRD5DRD3DRD4 | |
| SCHEMBL14703834 | 0.88 | DRD1 (1.00) | DRD2DRD1DRD5DRD3RAD52 | |
| Coreximine SCHEMBL30473249 | 0.88 | DRD1 (1.00) | DRD2DRD1DRD5DRD3RAD52 | |
| SCHEMBL14703833 | 0.88 | DRD1 (1.00) | DRD2DRD1DRD5DRD3RAD52 | |
| SCHEMBL30298995 | 0.88 | DRD1 (1.00) | DRD2DRD1DRD5DRD3RAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3154968-B1 | OXIDATIVE DEAROMATIZATION OF BERBINES | SpecGx LLC (US) | 2020-08-05 | — | — | EP | disclosed |
| US-9856251-B2 | Substituted berbines and processes for their synthesis | MALLINCKRODT LLC (US) | 2018-01-02 | — | — | US | disclosed |
| US-9593111-B2 | Oxidative dearomatization of berbines | MALLINCKRODT LLC (US) | 2017-03-14 | — | — | US | disclosed |
| US-20160347747-A1 | SUBSTITUTED BERBINES AND PROCESSES FOR THEIR SYNTHESIS | MALLINCKRODT INC. | 2016-12-01 | — | — | US | disclosed |
| US-20160347747-A1 | SUBSTITUTED BERBINES AND PROCESSES FOR THEIR SYNTHESIS | MALLINCKRODT INC. | 2016-12-01 | — | — | US | disclosed |
| US-9458109-B2 | Substituted berbines and processes for their synthesis | MALLINCKRODT LLC (US) | 2016-10-04 | — | — | US | disclosed |
| US-9458109-B2 | Substituted berbines and processes for their synthesis | MALLINCKRODT LLC (US) | 2016-10-04 | — | — | US | disclosed |
| WO-2015191837-A1 | OXIDATIVE DEAROMATIZATION OF BERBINES | MALLINCKRODT LLC (US) | 2015-12-17 | — | — | WO | disclosed |
| US-20150361076-A1 | OXIDATIVE DEAROMATIZATION OF BERBINES | STRATATECH CORPORATION | 2015-12-17 | — | — | US | disclosed |
| US-9181237-B2 | Substituted berbines and their synthesis | MALLINCKRODT LLC (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150099772-A1 | SUBSTITUTED BERBINES AND THEIR SYNTHESIS | SUCAMPO PHARMA AMERICAS LLC | 2015-04-09 | — | — | US | disclosed |
| WO-2010028004-A2 | SUBSTITUTED BERBINES AND PROCESSES FOR THEIR SYNTHESIS | MALLINCKRODT INC. (US) | 2010-03-11 | — | — | WO | disclosed |
| US-20100056789-A1 | Substituted Berbines and Processes for their Synthesis | MALLINCKRODT INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056789-A1 | Substituted Berbines and Processes for their Synthesis | MALLINCKRODT INC. (US) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160347747-A1 | SUBSTITUTED BERBINES AND PROCESSES FOR THEIR SYNTHESIS | TYMS, BLVRB, DHPS | DRD2 1069/4885DRD1 1322/4885DRD5 1340/4885 |
| US-20150361076-A1 | OXIDATIVE DEAROMATIZATION OF BERBINES | UNG, OGG1, ALKBH2 | DRD2 1773/4885DRD1 1934/4885DRD5 1788/4885 |
| US-20100056789-A1 | Substituted Berbines and Processes for their Synthesis | TYMS, BLVRB, DHPS | DRD2 1069/4885DRD1 1322/4885DRD5 1340/4885 |
| US-20150099772-A1 | SUBSTITUTED BERBINES AND THEIR SYNTHESIS | TYMS, NME2, TYMP | DRD2 2522/4885DRD1 2936/4885DRD5 3036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.